Talking biopharmaceuticals, biotechnology, bioprocessing and related pharma manufacturing.
Joined March 2011
- Tweets6.7K
- Following282
- Followers3.6K
- Likes144
Pinned Tweet
Our latest survey of #biopharma professionals on #DigitalTransformation in the industry uncovered a hype-actual adoption gap.
Get the full industry report at lnkd.in/eeSbk4ba
#AI
Cell therapy developers are pivoting from ex vivo to in vivo CAR-T.
A 2026 review projects in vivo could cut treatment-course costs by 50% or more. Still a projection.
馃敆 What in vivo still has to prove (free sign-in): hubs.li/Q04BTkQR0
#BioPharm #CellTherapy
Can we trust agentic AI for risk assessment? Traceable evidence, transparent decisions, and verifiable outcomes are essential.
馃帴 Learn more from Insilica CEO Thomas Luechtefeld ahead of @AAPSComms #PharmSci360: hubs.li/Q04BYS3j0
#AgenticAI #DrugDevelopment
How can biomarker testing improve access to targeted cancer therapies? @bmsnews鈥檚 Dr @n8pennell explains key barriers in precision oncology, from tissue collection to patient education.
馃帴 Learn more: hubs.li/Q04BBHR40
#PrecisionOncology #BiomarkerTesting #CancerResearch
At #ACG2026, @Odyssey_Tx is presenting a phase 2a trial design evaluating oral RIPK2 inhibitor OD-001 plus vedolizumab in moderate-to-severe UC. Topline induction results are expected in H2 2027.
馃憠 Read now: hubs.li/Q04zWMK10
#UlcerativeColitis #DrugDevelopment
ALT 3D medical illustration of a man's inflamed colon | Image credit: 漏 Sebastian Kaulitzki - 漏 Sebastian Kaulitzki - stock.adobe.com
Today's BioPharm Brief covers FDA-approved atezolizumab for stage 3 dMMR colon cancer, positive phase 3 data for thyroid eye disease, and petrelintide鈥檚 weight-loss results in phase 2b testing.
馃帶 Listen now: hubs.li/Q04zQpcv0
#DrugDevelopment #ClinicalTrials #Biopharma
Dr. Nathan Pennell of Bristol Myers Squibb explains why MRD-negative complete response matters as longer patient survival delays traditional clinical trial endpoints.
馃帴 Watch his interview now: hubs.ly/Q04zN7hy0
#MultipleMyeloma #ClinicalTrials
The latest BioPharm Brief covers rare disease drug development: @RocketPharma鈥檚 RP-A501 gene therapy trial, $47M for cell-based mRNA manufacturing, and @ultragenyx鈥檚 $210M FDA priority review voucher sale.
馃帶 Listen now! hubs.li/Q04zHfRy0
#GeneTherapy #RareDisease
Our latest podcast covers @FDA breakthrough designations for @abbvie鈥檚 Temab-A, expanded biosimilar manufacturing, @Celltrioninc鈥檚 Omlyclo launch, and @CaribouBio鈥檚 allogeneic CAR-T setback.
馃帶 Listen now: hubs.li/Q04zxhn90
#Biopharma #DrugDevelopment #CellTherapy
On today's podcast, The BioPharm Brief covers AL050 for Parkinson disease, a rare kidney disease partnership, VK2735 obesity dosing strategies, and phase 3 lymphoma data for epcoritamab + R-CHOP.
馃帶 Listen now: hubs.li/Q04zm_vG0
#Biopharma #DrugDevelopment #ClinicalTrials
Our latest podcast covers new obesity data for survodutide, expanded biosimilar capacity, an FDA review delay tied to facility remediation, and longer-term litifilimab data. 馃帶 Listen to the latest episode: hubs.li/Q04zdyNN0
#Biopharma #DrugDevelopment #ClinicalTrials
How does peptide length affect drug development and influence its regulation? Hear what LumaLex Law's Dustin Robinson has to say.
馃憠 Watch the full interview to learn more: hubs.li/Q04z4YZf0
#PeptideDrugs #DrugDevelopment #Biopharmaceuticals
Choosing the right manufacturing partner is critical as demand for sterile injectables grows. Discover how Simtra BioPharma Solutions is expanding U.S. capacity and capabilities to help customers prepare for what鈥檚 next. #Biopharma
hubs.ly/Q04yk4Dg0
Characterizing complex biotherapeutics requires advanced LC-MS strategies. Explore workflows designed to detect and identify trace-level PQAs, aggregates, sequence variants, and conjugation sites with up to 10X greater MS sensitivity. #LCMS
hubs.li/Q04xZ13M0
Chain mispairing. Low titers. Purification headaches. Which bispecific CMC challenge is slowing your program down?
See how an integrated platform is solving for it: hubs.li/Q04xyZ1V0
The latest episode of The BioPharm Brief covers @EliLillyandCo鈥檚 weekly insulin approval, @IPECAMER's standardized excipient data sharing, and Daiichi Sankyo and @Merck鈥檚 SCLC ADC setback. 馃帶 Listen now: hubs.li/Q04yw1k90
#Biopharma #DrugDevelopment #Oncology
馃憘 Did you hear? FDA has formalized a broader role for non-animal testing methods in drug development, including organ-on-chip systems and computer modeling. What could this mean for preclinical research?
馃憠 Read more: hubs.li/Q04y7WxJ0
#NAMs #PreclinicalResearch
ALT FDA headquarters at White Oak Campus in Silver Spring, Maryland, USA - January 13, 2020. The United States Food and Drug Administration (FDA) is a federal agency. | Image credit: 漏 JHVEPhoto - 漏 JHVEPhoto - stock.adobe.com
Bispecific antibodies are one of biopharma's fastest growing modalities, but chain mispairing, low titers, and analytical complexity keep slowing CMC development.
See how an integrated platform is tackling these bottlenecks: hubs.li/Q04xyTzc0
How are biopharma companies managing raw material risk in advanced therapies? @FDA, @genentech, and @MinarisRM discuss material qualification, supplier oversight, risk-based testing, and GMP expectations. Read more: hubs.li/Q04xSNsk0
#CellGeneTherapy #PDAFDA #GMP
How should biopharma companies validate AI in manufacturing? At PDA/FDA 2026, FDA, Sanofi, and Gilead addressed AI readiness, risk-based validation, data integrity, and quality oversight. Learn more: hubs.li/Q04xJ0Xy0
#AIinPharma #Biopharma #Pharma
ALT Global health safety regulation Concept, Businesswoman reviewing and approving FDA standard documents for medical and food, Compliance, laboratory inspection, certification, and international approval | Image credit: 漏 Ticha - 漏 Ticha - stock.adobe.com
From vision to commercialization, the right CDMO partner can help de-risk development and accelerate launch. Explore how Rentschler Biopharma鈥檚 dual-site capabilities and 50 years of biologics expertise support client success. #Biopharma
hubs.li/Q04wfzWN0
